Time-Dependent Prognostic Impact of Circulating Tumor Cells Detection in Non-Metastatic Breast Cancer: 70-Month Analysis of the REMAGUS02 Study
Table 1
Univariate and multivariate analysis on survival.
Adverse prognostic factors
patients/ total
DMFS univariate analysis value
DMFS multivariate analysis RR, 95% CI, value
OS univariate analysis value
OS multivariate analysis RR, 95% CI, value
Age ≤50 years
41/115
NS (0.99)
—
NS (0.51)
—
Tumor size T3 or T4
53/115
NS (0.13)
—
NS (0.28)
—
Clinical node N1 or N2
73/115
NS (0.64)
—
NS (0.49)
—
Tumor grade III
55/115
NS (0.76)
—
NS (0.55)
—
HR negative
47/115
NS (0.26)
—
0.01
Not included*
HER2 negative
81/115
NS (0.11)
—
0.04
Not included*
Triple negative phenotype
31/115
0.02
RR = 2.4 0.9–6
0.0003
RR = 5.4 1.6–18
Prechemotherapy ≥1 CTC/7.5 mL
22/95
0.04
RR = 2.4 0.9–6
0.03
RR = 3.0 1.0–9.5
Postchemotherapy ≥1 CTC/7.5 mL
15/85
NS (0.29)
—
NS (0.30)
—
Absence of pCR
93/114
NS (0.27)
—
NS (0.68)
—
DMFS: distant metastasis-free survival. OS: overall survival. 95% CI: 95% confidence interval. HR: hormone receptors. NS: nonsignificant. *HR and HER2 statuses, which are redundant to triple negative phenotype, were not included in multivariate analysis.
